摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-[2-[4-ethyl-6-[3-(methoxymethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]pyrimidin-5-yl]ethynyl]pyridin-2-amine | 1321872-71-2

中文名称
——
中文别名
——
英文名称
5-[2-[4-ethyl-6-[3-(methoxymethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]pyrimidin-5-yl]ethynyl]pyridin-2-amine
英文别名
——
5-[2-[4-ethyl-6-[3-(methoxymethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]pyrimidin-5-yl]ethynyl]pyridin-2-amine化学式
CAS
1321872-71-2
化学式
C20H22N8O
mdl
——
分子量
390.448
InChiKey
JVYJHDXPXXOPEW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    29
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.35
  • 拓扑面积:
    108
  • 氢给体数:
    1
  • 氢受体数:
    8

文献信息

  • [EN] 5-ALKYNYL PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS<br/>[FR] 5-ALCYNYL PYRIMIDINES ET LEUR UTILISATION COMME INHIBITEURS DE KINASES
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2011092197A1
    公开(公告)日:2011-08-04
    The present invention encompasses compounds of general formula (1) wherein R1 to R4 R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    本发明涵盖了一般式(1)中R1至R4 R3如权利要求1所定义的化合物,这些化合物适用于治疗以细胞过度或异常增殖为特征的疾病,并用于制备具有上述特性的药物。
  • 5-ALKYNYL-PYRIMIDINES
    申请人:SCHNEIDER Siegfried
    公开号:US20120028958A1
    公开(公告)日:2012-02-02
    The present invention encompasses compounds of general formula (1) wherein R 1 to R 4 R 3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    本发明涵盖了一般式(1)中定义的化合物,其中R1至R4R3如权利要求1中所定义,适用于治疗以细胞过度或异常增殖为特征的疾病,并用于制备具有上述特性的药物的用途。
  • 5-Alkynyl pyrimidines ahd their use as kinase inhibitors.
    申请人:Boehringer Ingelheim International GmbH
    公开号:EP2528910B1
    公开(公告)日:2015-03-18
查看更多

同类化合物

叔-丁基3-溴-8,9-二氢-5H-[1,2,4]三唑并[4,3-D][1,4]二氮杂卓-7(6H)-甲酸基酯 叔-丁基3-(羟甲基)-7,8-二氢-4H-[1,2,3]三唑并[1,5-A][1,4]二氮杂卓-5(6H)-甲酸基酯 乙基4-(4H-[1,2,4]三唑并[4,3-a][1,5]苯并二氮卓-5-基)哌嗪-1-羧酸酯 9H-[1,2,4]三唑并[4,3-a][1,4]二氮杂卓 9-氯-5,6-二氢-4-甲基-1-(2-噻吩基)-4H-[1,2,4]三唑并[4,3-a][1,5]苯并二氮杂卓 9-氯-1-(2-呋喃基)-5,6-二氢-4-甲基-4H-[1,2,4]三唑并[4,3-a][1,5]苯并二氮杂卓 8-氯-5-(4-甲基哌嗪-1-基)-6-苯基-[1,2,4]三唑并[4,3-a][1,5]苯并二氮杂卓 8-氯-1-甲基-5-(甲基硫烷基)-6-苯基-6H-[1,2,4]三唑并[4,3-a][1,5]苯并二氮卓 2-[(8-氯-6-苯基-6H-[1,2,4]三唑并[4,3-a][1,5]苯并二氮卓-5-基)硫烷基]-N,N-二甲基乙胺 2-[(8-氯-1-甲基-6-苯基-[1,2,4]三唑并[4,3-a][1,5]苯并二氮杂卓-5-基)硫基]-N,N-二甲基乙胺 1H-环丙并[d][1,2,4]三唑并[4,3-b]哒嗪 1H,5H-[1,2,4]三唑并[1,2-a][1,2]二氮杂卓-1,3,5(2H)-三酮,6,9-二氢-2,7-二甲基-9-(2-吡啶基)- (9ci)-1H-1,2,4-噻唑并[4,3-c][1,3]二氮杂卓 (9ci)-1H-1,2,4-噻唑并[4,3-a][1,4]二氮杂卓 3-(Trifluoromethyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-D][1,4]diazepine [1,4-dioxy-3-(pyrrolidine-1-carbonyl)-quinoxalin-2-ylmethylene]-hydrazinecarboxylic acid methyl ester 2-methyl-hexahydro-6-thia-2,3a,7c-triaza-4,4e-cyclo-cyclopenta[1,3]cyclopropa[1,2-a]cyclopropa[cd]-as-indacene-1,3-dione 2-methyl-6,6-dioxo-octahydro-6λ6-thia-2,3a,7c-triaza-4,4e-cyclo-cyclopenta[1,3]cyclopropa[1,2-a]cyclopropa[cd]-as-indacene-1,3-dione (4as,4a1r,8aR,13aS)-11-methyldodecahydro-10H-heptaleno[1',10':3,4,5]pyrazolo[1,2-a][1,2,4]triazole-10,12(11H)-dione 8-chloro-1-methyl-6-phenyl-4H-<1,2,4>triazolo<4,3-a><1,5>benzodiazepine-5(6H)-thione N-methyl-4-oxa-8,9,13-triazaheptacyclo<9.5.1.02,6.02,10.06,14.07,12.013,17>heptadecane-8,9-dicarboximide 8-(octyloxy)-4,5-dihydrobenzo[b][1,2,4]triazolo[4,3-d][1,4]thiazepine 1,3,4-trimethyl-7-oxy-8-phenyl-4,6-dihydro-1H-pyrazolo[4,3-e][1,4]diazepin-5-one 7-methyl-6,7-dihydro-5H-benzo[f][1,2,4]triazolo[4,3-d][1,4]diazepine 1-methyl-6-phenyl-4,6-dihydro-benzo[b][1,2,4]triazolo[4,3-d][1,4]diazepin-5-one 4,4-dimethyl-10-phenyl-hexahydro-1,7;2,6-dicyclo-dicyclobuta[c,e]cyclopenta[d][1,2,4]triazolo[1,2-a]pyridazine-9,11-dione 2-[3-[(3,4-dichlorophenyl)methyl]-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-N-(oxan-4-yl)-5-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-4-amine 3-{5H,6H,8H-[1,2,4]triazolo[3,4-c][1,4]oxazin-3-yl}azetidine,bis(trifluoroaceticacid) 1-cyclohexyl-4-methyl-5,6-dihydro-4H-benzo[b][1,2,4]triazolo[4,3-d][1,4]diazepine 8-chloro-1-cyclohexyl-4-methyl-5,6-dihydro-4H-benzo[b][1,2,4]triazolo[4,3-d][1,4]diazepine 2-phenyl-4-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)-3H-benzo[b][1,4]diazepine (1α,7α,8β,11β)-syn-14-acetamido-4-methyl-2,4,6-triazatetracyclo<5.4.2.18,11.02,6>tetradecane-3,5-dione 9-chloro-1-(2,4-dichloro-phenyl)-4-methyl-5,6-dihydro-4H-benzo[b][1,2,4]triazolo[4,3-d][1,4]diazepine 12-(Hydroxyimino)-5-methyl-3,5,7-triazahexacyclo<7.5.02,13.03,7.08,11.010,14>tetradecane-4,6-dione 4-(benzyloxy)-1-methyl-8-chloro-6-phenyl-4H-s-triazolo[4,3-a][1,5]benzodiazepin-5-one 4-((R)-3-morpholin-4-yl-1-phenylsulfanylmethyl-propylamino)-N-(5,6,7,8-tetrahydro-4H-1,2,3a,6-tetraaza-azulen-3-yl)-3-trifluoromethanesulfonyl-benzenesulfonamide 7-[5-chloro-4-(1-methyl-1H-benzimidazol-2-yl)pyridin-2-yl]-3-cyclopropyl-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-d][1,4]diazepine tert-butyl 4-[(1R)-1-({[(6S)-6-(5-chloro-2-methoxybenzyl)-3,7-dioxo-6,7-dihydro-5H-[1,2,4]oxadiazolo[4,3-a][1,4]diazepin-8(9H)-yl]carbonyl}amino)propyl]-2-nitrobenzoate (32Z,51Z,71Z)-35,55,74-trimethyl-1(1,3)-benzena-3,5,7(1,3)-tricyclopentanacyclooctaphane-32,34,51,53,71,74-hexaene 7-methyl-4b,4c,4d,4e,5,8b-hexahydro-5a,7,8a-triaza-4a,5-cyclo-benzo[1,3]cyclopropa[1,2-a]cyclopropa[cd]-as-indacene-2,6,8-trione 2-[3-(2,4-Dibromo-phenyl)-5-phenyl-3H-[1,3,4]thiadiazol-(2E)-ylidene]-pentan-3-one 8-chloro-6-(2-chloro-phenyl)-1-methyl-4,6-dihydro-benzo[b][1,2,4]triazolo[4,3-d][1,4]diazepin-5-one 5-methyl-3,5,7-triazahexacyclo<7.5.0.02,13.03,7.08,11.010,14>tetradecane-4,6,12-trione 6,6a,6b,7,8,10,12a,12b-octahydro-2H,5H-bis[1,2,4]triazolo[4,3-a;4',3'-a']cyclobuta[1,2-c;3,4-e']dipyridine-3,11-dione 4-(3-aminopropyl)-1-methyl-8-chloro-6-phenyl-4H-s-triazolo-[4,3-a][1,5]benzodiazepin-5-one